Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 14/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 14/20 | 0.46 |
| ▸ | DAO | P14920 | 1/20 | 0.37 |
| ▸ | TNF | P01375 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.36 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | CA3 | P07451 | 1/20 | 0.34 |
| ▸ | CA6 | P23280 | 1/20 | 0.34 |
| ▸ | CA5A | P35218 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24857743 | 0.81 | ESR1 (0.41) | ESR1ESR2DAOTNFRIPK1 | |
| SCHEMBL24176055 | 0.81 | ESR1 (0.41) | ESR1ESR2DAOTNFRIPK1 | |
| SCHEMBL24663180 | 0.81 | CYP3A4 (0.47) | ESR1ESR2TNFRIPK1 | |
| SCHEMBL25040847 | 0.80 | ESR1 (0.40) | ESR1ESR2NQO2ABCB1CA3 | |
| SCHEMBL31609498 | 0.79 | ESR1 (0.39) | ESR1ESR2DAOTNFRIPK1 | |
| SCHEMBL26059134 | 0.79 | ESR1 (0.39) | ESR1ESR2DAOTNFRIPK1 | |
| SCHEMBL24176030 | 0.79 | GABRA1 (0.40) | ESR1ESR2TNFRIPK1 | |
| SCHEMBL24680259 | 0.78 | ESR1 (0.48) | ESR1ESR2DAOTNFRIPK1 | |
| SCHEMBL27044363 | 0.78 | ESR1 (0.38) | ESR1ESR2TNFRIPK1 | |
| SCHEMBL27428606 | 0.78 | ESR1 (0.38) | ESR1ESR2TNFRIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035389-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-25 | — | — | US | disclosed |
| US-12421253-B2 | Tetrahydropyridopyrimidine pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20240376127-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. | 2024-11-14 | — | — | US | disclosed |
| US-11999753-B2 | Tetrahydropyridopyrimidine pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2024-06-04 | — | — | US | disclosed |
| EP-4262807-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-10-25 | — | — | EP | disclosed |
| CN-116829151-A | Azaquinazoline pan KRAS inhibitors | 米拉蒂治疗股份有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20230072276-A1 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. | 2023-03-09 | — | — | US | disclosed |
| US-20220194961-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| US-20220194961-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. | 2022-06-23 | — | — | US | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
| WO-2022132200-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240376127-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | ESR1 2385/4885ESR2 4178/4885DAO 4481/4885 |
| US-12421253-B2 | Tetrahydropyridopyrimidine pan-KRas inhibitors | KRAS, NRAS, HRAS | ESR1 2385/4885ESR2 4178/4885DAO 4481/4885 |
| US-11999753-B2 | Tetrahydropyridopyrimidine pan-KRas inhibitors | KRAS, NRAS, HRAS | ESR1 2385/4885ESR2 4178/4885DAO 4481/4885 |
| US-20220194961-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | ESR1 2385/4885ESR2 4178/4885DAO 4481/4885 |
| US-20230072276-A1 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | ESR1 2319/4885ESR2 4007/4885DAO 4724/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | ESR1 2319/4885ESR2 4007/4885DAO 4724/4885 |
| US-20260035389-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | ESR1 3922/4885ESR2 3564/4885DAO 3666/4885 |
| US-20250388606-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | ESR1 2741/4885ESR2 3702/4885DAO 3652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.